ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EMBCV Embecta Corporation

33.33
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Embecta Corporation NASDAQ:EMBCV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 33.33 33.25 35.44 0 01:00:00

embecta Announces Earnings Conference Call Information for the Third Quarter of Fiscal Year 2022

05/07/2022 10:00pm

GlobeNewswire Inc.


Embecta (NASDAQ:EMBCV)
Historical Stock Chart


From Jul 2021 to Jul 2024

Click Here for more Embecta Charts.

Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that it will report its financial results for the third quarter of fiscal year 2022 before the market opens on Monday, August 15, 2022.

Management will host a conference call at 8:00 a.m. Eastern Time (ET) on August 15 to discuss the results of the quarter, provide an operational update, and host a question and answer session.

Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.

A webcast replay of the call will be available beginning at 11:00 a.m. ET on August 15, 2022, via the embecta investor relations website and archived on the website for one year.

About embecta embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.

CONTACTS  Investors:Pravesh KhandelwalVP, Head of Investor Relations551-264-6547Contact IR

Media: Christian GlazarSr. Director, Corporate Communications 908-821-6922 Contact Media Relations 

1 Year Embecta Chart

1 Year Embecta Chart

1 Month Embecta Chart

1 Month Embecta Chart

Your Recent History

Delayed Upgrade Clock